![How Cerebral and Alto Neuroscience embarked on an at-home clinical trial for depression | TechCrunch How Cerebral and Alto Neuroscience embarked on an at-home clinical trial for depression | TechCrunch](https://techcrunch.com/wp-content/uploads/2021/12/GettyImages-1319228438.jpg)
How Cerebral and Alto Neuroscience embarked on an at-home clinical trial for depression | TechCrunch
![Phase I dose-escalation single centre clinical trial to evaluate the safety of infusion of memory T cells as adoptive therapy in COVID-19 (RELEASE) - eClinicalMedicine Phase I dose-escalation single centre clinical trial to evaluate the safety of infusion of memory T cells as adoptive therapy in COVID-19 (RELEASE) - eClinicalMedicine](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/d763732d-acff-446e-872e-e81d6e44f06f/gr1_lrg.jpg)
Phase I dose-escalation single centre clinical trial to evaluate the safety of infusion of memory T cells as adoptive therapy in COVID-19 (RELEASE) - eClinicalMedicine
![Effectively Conducting Oncology Clinical Trials During the COVID-19 Pandemic - Advances in Radiation Oncology Effectively Conducting Oncology Clinical Trials During the COVID-19 Pandemic - Advances in Radiation Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/7590baad-dcc7-4154-b171-aabee1c16daa/gr2_lrg.jpg)
Effectively Conducting Oncology Clinical Trials During the COVID-19 Pandemic - Advances in Radiation Oncology
![The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial - The Lancet The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial - The Lancet](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/3188c36b-9a69-4509-9116-c8797795272b/gr1.gif)
The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial - The Lancet
![Formative research to design a culturally-appropriate cancer clinical trial education program to increase participation of African American and Latino communities | BMC Public Health | Full Text Formative research to design a culturally-appropriate cancer clinical trial education program to increase participation of African American and Latino communities | BMC Public Health | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12889-020-08939-4/MediaObjects/12889_2020_8939_Fig1_HTML.png)